Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Large GWAS Pinpoints Ovarian Cancer Risk Genes

By LabMedica International staff writers
Posted on 13 May 2019
Results of a large genome-wide association study identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer.

The current study, which was carried out by investigators at the University of California, Los Angeles (USA) and the Dana-Farber Cancer Institute (Boston, MA, USA), continued the assessment of large-scale genetic data that had been gathered over a period of more than 10 years by the Ovarian Cancer Association Consortium. More...
Those investigators had found more than 30 regions in the genome associated with ovarian cancer after having compared the genetic profiles of about 25,000 women with ovarian cancer and 45,000 control subjects.

Applying advanced analytical tools, the current team of investigators identified 34 genes that were associated with an increased risk for developing ovarian cancer. Furthermore, this study implicated at least one target gene for six out of 13 distinct genome-wide association study regions and pinpointed 23 new candidate susceptibility genes for high-grade serous ovarian cancer.

"If you detect ovarian cancer really early, then the survival rate is very high, nearly 90% percent," said contributing author Dr. Bogdan Pasaniuc, associate professor of pathology and laboratory medicine at the University of California, Los Angles. "But that does not happen often. Most cases are found at a later stage and survival drops dramatically. That is why we want to understand the genetics behind it - so we can do a better job at predicting who is at a higher risk of developing this cancer."

"Whenever you inherit a piece of DNA from your parents, you do not inherit just every base pair of the genome, you inherit big chunks," said Dr. Pasanuic. "That means that if you inherit a gene mutation in a given region, you inherit the entire region, which can carry 10 to 20 genes at a time. This makes it very hard to pinpoint specific genes from specific regions. With the identification of these genes, we now have a narrow list of genes that can help us better predict ovarian cancer risks in women who may have never known that they were at a higher risk for developing the disease. While we are not there yet, we are hoping this study will lead to better outcomes because we will be able to monitor women earlier, when the cancer is easier to treat."

The ovarian cancer study was published in the May 1, 2019, online edition of the journal Nature Genetics.

Related Links:
University of California, Los Angeles
Dana-Farber Cancer Institute


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.